A phase I, randomized, double-blind, dose-ranging, crossover trial of HCV vaccine (TG4040) in patients with chronic hepatitis C to be conducted in two parts

Trial Profile

A phase I, randomized, double-blind, dose-ranging, crossover trial of HCV vaccine (TG4040) in patients with chronic hepatitis C to be conducted in two parts

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2008

At a glance

  • Drugs TG 4040 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Sep 2008 Primary outcome identified as safety and virological response as reported by ClinicalTrials.gov.
    • 14 Sep 2008 Planned end date added (1 Sep 2007) as reported by ClinicalTrials.gov.
    • 18 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top